Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: A pilot study of patients with hepatitis B virus-related cirrhosis

Journal of Gastroenterology

Volumn 41, Issue 12, 2006, Pages 1206-1213

  Someya, Takashi ^a,b   Ikeda, Kenji ^a,b   Saitoh, Satoshi ^a,b   Kobayashi, Masahiro ^a,b   Hosaka, Tetsuya ^a,b   Sezaki, Hitomi ^a,b   Akuta, Norio ^a,b   Suzuki, Fumitaka ^a,b   Suzuki, Yoshiyuki ^a,b   Arase, Yasuji ^a,b   Kumada, Hiromitsu ^a,b  

^a TORANOMON HOSPITAL   (Japan)

^b Okinaka Memorial Institute for Medical Research   (Japan)

Author keywords

Aspartate aminotransferase; Cirrhosis; HBVDNA; Hepatocellular carcinoma; Interferon; Prevention; Recurrence

Indexed keywords

ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; VIRUS DNA; ANTINEOPLASTIC AGENT; INTERFERON;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; BLOOD; CATHETER ABLATION; GENETICS; LIVER TUMOR; MICROBIOLOGY; MIDDLE AGED; PILOT STUDY; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS;

EID: 33947577080     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-006-1912-0     Document Type: Article

References (34)

1. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2000). WHO Web site (www.who.int); 2000
2. AS Lok 2002 Chronic hepatitis B N Engl J Med 346 1682-3 12037146 10.1056/ NEJM200205303462202
3. FJ Mahoney 1999 Update on diagnosis, management, and prevention of hepatitis B virus infection Clin Microbiol Rev 12 351-66 10194463 1:STN:280:DyaK1M3ht1SmsA%3D%3D
4. WM Lee 1997 Hepatitis B virus infection N Engl J Med 337 1733-45 9392700 10.1056/NEJM199712113372406 1:STN:280:DyaK1c%2FktFyjtA%3D%3D
5. DM Parkin F Bray J Ferlay P Pisani 2001 Estimating the world cancer burden: Globocan 2000 Int J Cancer 94 153-6 11668491 10.1002/ijc.1440 1:CAS:528:DC%2BD3MXntVGlu78%3D
6. W Weimar RA Heijtink FJ ten Kate SW Schalm N Masurel H Schellekens 1980 Double-blind study of leukocyte interferon administration in chronic HBsAg-positive hepatitis Lancet 1 336-8 6101791 10.1016/ S0140-6736(80)90885-5 1:STN:280:Bi%2BC3MbkvF0%3D
7. GJ Alexander EA Fagan P Guarner N Rolando J Brahm AL Eddleston 1986 A controlled trial of 6 months thrice weekly lymphoblastoid interferon versus no therapy in chronic hepatitis B virus infection J Hepatol 3 Suppl 2 S183-8 3298406 10.1016/S0168-8278(86)80118-0
8. GM Dusheiko AC Paterson L Pitcher C Kassianides AM DiBisceglie E Song 1986 Recombinant leucocyte interferon treatment of chronic hepatitis B. An analysis of two therapeutic trials J Hepatol 3 Suppl 2 S199-207 3298408 10.1016/S0168-8278(86)80121-0
9. JH Hoofnagle GM Dusheiko LB Seeff EA Jones JG Waggoner ZB Bales 1981 Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis Ann Intern Med 94 744-8 7235415 1:STN:280:Bi6B3crjvVw%3D
10. AS Lok IV Weller P Karayiannis D Brown MJ Fowler J Monjardino 1984 Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication Liver 4 45-9 6700383 1:STN:280:BiuC2c%2FpvVQ%3D
11. J Korenman B Baker J Waggoner JE Everhart AM Di Bisceglie JH Hoofnagle 1991 Long-term remission of chronic hepatitis B after alpha-interferon therapy Ann Intern Med 114 629-34 2003708 1:STN:280:By6C28nhs1c%3D
12. JB Wong RS Koff F Tine SG Pauker 1995 Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B Ann Intern Med 122 664-75 7702228 1:STN:280:ByqB3MnnvFE%3D
13. GM Dusheiko JA Roberts 1995 Treatment of chronic type B and C hepatitis with interferon alpha: An economic appraisal Hepatology 22 1863-73 7489999 10.1016/0270-9139(95)90216-3 1:CAS:528:DyaK28XmvV2rsQ%3D%3D
14. SPSS Inc. SPSS for Windows version 11.0 manual. SPSS: Chicago; 2001
15. M Omata H Yoshida 2004 Prevention and treatment of hepatocellular carcinoma Liver Transpl 10 S111-4 14762850 10.1002/lt.20046
16. K Ikeda Y Arase M Kobayashi T Someya S Saitoh Y Suzuki 2003 Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients Intervirology 46 96-104 12684548 10.1159/ 000069744 1:CAS:528:DC%2BD3sXisleqtL0%3D
17. B Tang WD Kruger G Chen F Shen WY Lin S Mboup 2004 Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers J Med Virol 72 35-40 14635008 10.1002/jmv.10559 1:CAS:528:DC%2BD2cXms1yrsr8%3D
18. RP Perrillo ER Schiff GL Davis HC Bodenheimer Jr K Lindsay J Payne 1990 A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group N Engl J Med 323 295-301 2195346 1:STN:280:By%2BA3cbpt10%3D
19. DK Wong AM Cheung K O'Rourke CD Naylor AS Detsky J Heathcote 1993 Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis Ann Intern Med 119 312-23 8328741 1:STN:280:ByyA3MbhvFc%3D
20. K Krogsgaard P Marcellin C Trepo P Berthelot JM Sanchez-Tapias M Bassendine 1996 Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group J Hepatol 25 803-13 9007706 10.1016/S0168-8278(96)80282-0 1:CAS:528:DyaK2sXotlCmsQ%3D%3D
21. K Ikeda S Saitoh Y Suzuki M Kobayashi A Tsubota M Fukuda 1998 Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus Cancer 82 827-35 9486570 10.1002/ (SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G 1:CAS:528:DyaK1cXhsVCrtrw%3D
22. SM Lin IS Sheen RN Chien CM Chu YF Liaw 1999 Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection Hepatology 29 971-5 10051505 10.1002/hep.510290312 1:CAS:528:DyaK1MXhvFyjsb8%3D
23. M Van Zonneveld P Honkoop BE Hansen HG Niesters SD Murad RA de Man 2004 Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B Hepatology 39 804-10 14999700 10.1002/hep.20128 1:CAS:528:DC%2BD2cXjtlaiu70%3D
24. MF Yuen CK Hui CC Cheng CH Wu YP Lai CL Lai 2001 Long-term follow-up of interferon alpha treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 139-45 11431745 10.1053/jhep.2001.25273 1:CAS:528:DC%2BD3MXltlKjsL4%3D
25. DT Lau J Everhart DE Kleiner Y Park J Vergalla P Schmid 1997 Long-term follow-up of patients with chronic hepatitis B treated with interferon alpha Gastroenterology 113 1660-7 9352870 10.1053/ gast.1997.v113.pm9352870 1:CAS:528:DyaK2sXnt1yhtr4%3D
26. JF Tsai JE Jeng MS Ho WY Chang MY Hsieh ZY Lin 1997 Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: A prospective study Br J Cancer 76 968-74 9328161 1:STN:280:ByiH28not1U%3D
27. GV Papatheodoridis E Manesis SJ Hadziyannis 2001 The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 34 306-13 11281561 10.1016/ S0168-8278(00)00094-5 1:CAS:528:DC%2BD3MXislCksbo%3D
28. P Lampertico M Vigano M Iavarone 2001 Long-term outcome of patients with HBeAg-negative chronic hepatitis B treated with a 24-month course of interferon alpha J Hepatol 34 Suppl 1 149
29. D Lavanchy 2004 Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 97-107 14996343 10.1046/j.1365-2893.2003.00487.x 1:STN:280:DC%2BD2c7gs1Whug%3D%3D
30. NIH Consensus Development Conference: Management of hepatitis C. Hepatology 1997;26:83-108
31. A Castilla J Prieto N Fausto 1991 Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alpha therapy N Engl J Med 324 933-40 1900574 1:CAS:528:DyaK3MXltleitLk%3D
32. JC Ryff 1995 Usefulness of interferon for treatment of hepatitis C J Hepatol 22 1 Suppl 101-9 7602060 1:STN:280:ByqA38rlsVI%3D
33. AA Dunk T Ikeda M Pignatelli HC Thomas 1986 Human lymphoblastoid interferon: In vitro and in vivo studies in hepatocellular carcinoma J Hepatol 2 419-29 3013985 10.1016/S0168-8278(86)80053-8 1:CAS:528:DyaL28XksVSrt7o%3D
34. CL Lai JY Lau PC Wu H Ngan HT Chung SJ Mitchell 1993 Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial Hepatology 17 389-94 8383088 10.1016/ 0270-9139(93)90049-S 1:STN:280:ByyC1cngs10%3D